Literature DB >> 8452358

Effects of interleukin-8 on nonspecific resistance to infection in neutropenic and normal mice.

M T Vogels1, I J Lindley, J H Curfs, W M Eling, J W van der Meer.   

Abstract

The effect of treatment with interleukin-8 (IL-8), a neutrophil-activating cytokine, was investigated in normal and neutropenic mice infected with a lethal dose of Pseudomonas aeruginosa, Klebsiella pneumoniae, or Plasmodium berghei. Intraperitoneal (i.p.) IL-8 treatment was associated with accelerated death when IL-8 was administered shortly before i.p. infection with P. aeruginosa or shortly after i.p. infection with P. aeruginosa and K. pneumoniae. Histopathological analyses demonstrated a tendency to more severe organ lesions in IL-8-treated mice. Only nonneutropenic mice that received IL-8 shortly before the infectious challenge and at the site of infection were protected by IL-8. Whether IL-8 is protective of or detrimental to the survival of infection appeared to depend on the presence of bacteria at the injection site and on the presence of neutropenia. IL-8 may be an important participant in the cascade of interacting cytokines that is induced by the lethal infectious challenge.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8452358      PMCID: PMC187652          DOI: 10.1128/AAC.37.2.276

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Synthesis and expression in Escherichia coli of the gene encoding monocyte-derived neutrophil-activating factor: biological equivalence between natural and recombinant neutrophil-activating factor.

Authors:  I Lindley; H Aschauer; J M Seifert; C Lam; W Brunowsky; E Kownatzki; M Thelen; P Peveri; B Dewald; V von Tscharner
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

2.  Enhancement of antibacterial resistance of neutropenic, bone marrow-suppressed mice by interleukin-1 alpha.

Authors:  K W McIntyre; J Unowsky; W DeLorenzo; W Benjamin
Journal:  Infect Immun       Date:  1989-01       Impact factor: 3.441

3.  Protection of neutropenic mice from lethal Candida albicans infection by recombinant interleukin 1.

Authors:  J W Van't Wout; J W Van der Meer; M Barza; C A Dinarello
Journal:  Eur J Immunol       Date:  1988-07       Impact factor: 5.532

4.  Prolonged elevation of interleukin-8 and interleukin-6 concentrations in plasma and of leukocyte interleukin-8 mRNA levels during septicemic and localized Pseudomonas pseudomallei infection.

Authors:  J S Friedland; Y Suputtamongkol; D G Remick; W Chaowagul; R M Strieter; S L Kunkel; N J White; G E Griffin
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

5.  Structure determination of a human lymphocyte derived neutrophil activating peptide (LYNAP).

Authors:  H Gregory; J Young; J M Schröder; U Mrowietz; E Christophers
Journal:  Biochem Biophys Res Commun       Date:  1988-03-15       Impact factor: 3.575

6.  Secretion of novel and homologous neutrophil-activating peptides by LPS-stimulated human endothelial cells.

Authors:  J M Schröder; E Christophers
Journal:  J Immunol       Date:  1989-01-01       Impact factor: 5.422

7.  A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal gram-negative infection.

Authors:  J W van der Meer; M Barza; S M Wolff; C A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

8.  Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor.

Authors:  K Matsushima; K Morishita; T Yoshimura; S Lavu; Y Kobayashi; W Lew; E Appella; H F Kung; E J Leonard; J J Oppenheim
Journal:  J Exp Med       Date:  1988-06-01       Impact factor: 14.307

9.  A novel neutrophil-activating factor produced by human mononuclear phagocytes.

Authors:  P Peveri; A Walz; B Dewald; M Baggiolini
Journal:  J Exp Med       Date:  1988-05-01       Impact factor: 14.307

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  7 in total

Review 1.  A primer on cytokines: sources, receptors, effects, and inducers.

Authors:  J H Curfs; J F Meis; J A Hoogkamp-Korstanje
Journal:  Clin Microbiol Rev       Date:  1997-10       Impact factor: 26.132

Review 2.  Natural pathogens of laboratory mice, rats, and rabbits and their effects on research.

Authors:  D G Baker
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

3.  Interleukin-8 controls bacterial transepithelial translocation at the cost of epithelial destruction in experimental shigellosis.

Authors:  P J Sansonetti; J Arondel; M Huerre; A Harada; K Matsushima
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

4.  Roles of tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, platelet-activating factor, and arachidonic acid metabolites in interleukin-1-induced resistance to infection in neutropenic mice.

Authors:  M T Vogels; C C Hermsen; H L Huys; W M Eling; J W van der Meer
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

5.  Role of acute-phase proteins in interleukin-1-induced nonspecific resistance to bacterial infections in mice.

Authors:  M T Vogels; L Cantoni; M Carelli; M Sironi; P Ghezzi; J W van der Meer
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

6.  Interleukin-1 (IL-1)-induced resistance to bacterial infection: role of the type I IL-1 receptor.

Authors:  M T Vogels; W M Eling; A Otten; J W van der Meer
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

Review 7.  Chemokines and their receptors in infectious disease.

Authors:  D H McDermott; P M Murphy
Journal:  Springer Semin Immunopathol       Date:  2000
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.